MRNA raises outlook
Moderna reported a revenue beat and positive diluted EPS, raised its full-year revenue growth and year-end cash outlook, lowered R&D spending, and added a new COO while completing convertible financing and a litigation settlement, with the stock moving violently higher.
Previous verdicts for MRNA
- AI Search: Moderna Rallies on Early Multiple Myeloma mRNA Data — 2026-11-04
- AI Search: Moderna Rallies Sharply on Vaccine Headlines as Market Slips — 2026-11-03
- AI Search: Moderna Shares Edge Up on Positive Meloma Trial Data and Analyst Boost — 2026-10-29
- AI Search: Fast-Track Status for RSV Vaccine Lifts Moderna Despite Downgrade — 2026-10-28
- AI Search: William Blair Downgrade Sends Moderna Sharply Lower — 2026-10-27
Ezbrisk weighs each event against the market reaction and publishes a verdict with an overreaction reading. How the methodology works